The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia
Open accessAbstract
Introduction: The aim of this study was to compare a 7-day course of doripenem to a 10-day course of imipenem-cilastatin for ventilator-associated pneumonia (VAP) due to Gram-negative bacteria. Methods: This was a prospective, double-blinded, randomized trial comparing a fixed 7-day course of doripenem one gram as a four-hour infusion every eight hours with a fixed 10-day course of imipenem-cilastatin one gram as a one-hour infusion every eight hours (April 2008 through June 2011). Results: The study was stopped prematurely at the recommendation of the Independent Data Monitoring Committee that was blinded to treatment arm assignment and performed a scheduled review of data which showed signals that were close to the pre-specified stopping limits. The final analyses included 274 randomized patients. The clinical cure rate at the end of therapy (EOT) in the microbiological intent-to-treat (MITT) population was numerically lower for patients in the doripenem arm compared to the imipenem-cilastatin arm (45.6% versus 56.8%; 95% CI, -26.3% to 3.8%). Similarly, the clinical cure rate at EOT was numerically lower for patients with Pseudomonas aeruginosa VAP, the most common Gram-negative pathogen, in the doripenem arm compared to the imipenem-cilastatin arm (41.2% versus 60.0%; 95% CI, -57.2 to 19.5). All cause 28-day mortality in the MITT group was numerically greater for patients in the doripenem arm compared to the imipenem-cilastatin arm (21.5% versus 14.8%; 95% CI, -5.0 to 18.5) and for patients with P. aeruginosa VAP (35.3% versus 0.0%; 95% CI, 12.6 to 58.0). Conclusions: Among patients with microbiologically confirmed late-onset VAP, a fixed 7-day course of doripenem was found to have non-significant higher rates of clinical failure and mortality compared to a fixed 10-day course of imipenem-cilastatin. Consideration should be given to treating patients with VAP for more than seven days to optimize clinical outcome. Trial Registration: ClinicalTrials.gov: NCT00589693
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408
Pugh, R., Grant, C., Cooke, R. P., & Dempsey, G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007577.pub3 · Cited by 289
Cited by
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Self-citationTorres, A., Niederman, M. S., Chastre, J., Ewig, S., Fernandez-Vandellos, P., Hanberger, H., Kollef, M., Li Bassi, G., Luna, C. M., Martin-Loeches, I., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00582-2017 · Cited by 1,387
Self-citationTorres, A., Cilloniz, C., Niederman, M. S., Menéndez, R., Chalmers, J. D., Wunderink, R. G., & van der Poll, T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00259-0 · Cited by 798
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update
Reynolds, D., & Kollef, M. (2021) · Drugs · doi:10.1007/s40265-021-01635-6 · Cited by 721
Self-citationGuilhaumou, R., Benaboud, S., Bennis, Y., Dahyot-Fizelier, C., Dailly, E., Gandia, P., Goutelle, S., Lefeuvre, S., Mongardon, N., Roger, C., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2378-9 · Cited by 543
Antibiotic stewardship in the intensive care unit
Luyt, C.-E., Bréchot, N., Trouillet, J.-L., & Chastre, J. (2014) · Critical Care · doi:10.1186/s13054-014-0480-6 · Cited by 388
Self-citationKollef, M. H., Nováček, M., Kivistik, Ü., Réa-Neto, Á., Shime, N., Martin-Loeches, I., Timsit, J.-F., Wunderink, R. G., Bruno, C. J., Huntington, J. A., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30403-7 · Cited by 345
Self-citationPugh, R., Grant, C., Cooke, R. P., & Dempsey, G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007577.pub3 · Cited by 289
Micek, S. T., Wunderink, R. G., Kollef, M. H., Chen, C., Rello, J., Chastre, J., Antonelli, M., Welte, T., Clair, B., Ostermann, H., et al. (2015) · Critical Care · doi:10.1186/s13054-015-0926-5 · Cited by 267
Self-citationRationalizing antimicrobial therapy in the ICU: a narrative review
Timsit, J.-F., Bassetti, M., Cremer, O., Daikos, G., de Waele, J., Kallil, A., Kipnis, E., Kollef, M., Laupland, K., Paiva, J.-A., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05520-5 · Cited by 266
Self-citationAntimicrobial-associated harm in critical care: a narrative review
Arulkumaran, N., Routledge, M., Schlebusch, S., Lipman, J., & Conway Morris, A. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05929-3 · Cited by 175
Timing of antibiotic therapy in the ICU
Kollef, M. H., Shorr, A. F., Bassetti, M., Timsit, J.-F., Micek, S. T., Michelson, A. P., & Garnacho-Montero, J. (2021) · Critical Care · doi:10.1186/s13054-021-03787-z · Cited by 161
Self-citationHanretty, A. M., & Gallagher, J. C. (2018) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2118 · Cited by 123
Royer, S., DeMerle, K. M., Dickson, R. P., & Prescott, H. C. (2018) · Journal of Hospital Medicine · doi:10.12788/jhm.2905 · Cited by 94
Tansarli, G. S., Andreatos, N., Pliakos, E. E., & Mylonakis, E. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02495-18 · Cited by 56
Arulkumaran, N., Khpal, M., Tam, K., Baheerathan, A., Corredor, C., & Singer, M. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004267 · Cited by 36
Metadata
- Authors
- Kollef, M. H., Chastre, J., Clavel, M., Restrepo, M. I., Michiels, B., Kaniga, K., Cirillo, I., Kimko, H., & Redman, R.
- Venue
- Critical Care
- Published
- 2012-11-13
- Volume
- 16
- Issue
- 6
- Pages
- R218-R218
- ISSN
- 1364-8535 (ISSN-L)
- OpenAlex
- W2150498285
- Cited by
- 208
- References
- 2
- FWCI
- 12.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.